Research Area: Cancer
Biological Activity:
Oxaliplatin (Eloxatin) is a 1,2-diaminocyclohexane (DACH) carrier ligand-based groups of platinum antitumor agent with IC50 of median 1.3, 6.2 and 1.5 mM for SW480 DLD1, HT29, respectively. Cytotoxicity of platinum agents is believed to result from the formation of platinum-DNA adducts. Eukaryotic cells respond to the presence of oxaliplatin adducts in DNA by activating signal transduction pathways that result in cell cycle arrest, an increase in DNA repair activity and apoptosis. Oxaliplatin was found to be active against C32 and G361 cell lines with IC50 values of 49.48 and 9.07 μM (1 h exposure), 9.47 and 1.30 μM (4 h exposure), and 0.98 and 0.14 μM (24 h exposure), respectively. [1][2][3]